FAQ on Soligenix Inc.'s Clinical Programs and Alliance Global Partners' Updated Valuation

What is the significance of Alliance Global Partners’ updated rating and price target for Soligenix Inc.?

The updated Buy rating and increased price target to $10 per share reflect confidence in Soligenix’s clinical programs, particularly HyBryte(TM) for CTCL and SGX945 for Behçet’s disease, indicating potential growth and success in these areas.

Why did Alliance Global Partners increase Soligenix’s price target?

The increase was based on the rising valuation of HyBryte(TM) for CTCL treatment and the new estimated valuation for SGX945, a treatment for Behçet’s disease, alongside compelling data from recent studies.

What is HyBryte(TM), and what condition does it treat?

HyBryte(TM) is a novel photodynamic therapy using safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease.

How does SGX945 perform in treating Behçet’s disease compared to alternatives?

SGX945 showed outcomes similar to or superior to Amgen’s Otezla(R) in decreasing oral ulcers at 4 weeks, with effects continuing through weeks 5–8 even after dosing stopped at the 4th week.

When are the topline results for Soligenix’s phase 3 FLASH2 trial expected?

Topline results for the phase 3 FLASH2 trial are expected to be announced next year, with the study continuing research from the initial phase 3 FLASH trial but with a longer treatment duration of 18 weeks.

What are the projected sales for HyBryte(TM) and SGX945?

HyBryte(TM) is projected to have U.S. sales of $75M by 2035 and ROW sales of $50M by 2036, while SGX945 for Behçet’s disease could reach $50M in sales by 2035.

What is the basis for Soligenix’s $10/share valuation?

The valuation is based on expectations for HyBryte(TM) launch in 2028, subsequent sales growth, SGX945’s potential, a U.S. government contract for RiVax(R), and cash and technology value.

Where can I view the full report from Alliance Global Partners?

The full report can be viewed at https://ibn.fm/6zX9x.

What is Soligenix Inc.’s focus?

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs, including CTCL and Behçet’s disease.